---
figid: PMC4088997__mt201427f5
figlink: /pmc/articles/PMC4088997/figure/fig5/
number: F5
caption: Rapamycin and paclitaxel nanoparticles synergistically target the PI3K/Akt/mTOR
  pathway by suppressing feedback loop Akt phosphorylation. Rapamycin nanoparticle
  treatment alone caused a decrease in phosphorylated S6 and S6K, as well as 4E-BP1,
  and an increase in pAkt through feedback loop activation. Rapamycin and paclitaxel
  delivered within the same nanoparticle also led to a decrease in phosphorylated
  S6, S6K, and 4E-BP1, but resulted in a decrease in pAkt. Combination therapy also
  inhibited phosphorylation of PRAS40, Bad, and GSK3β, all previously shown to increase
  with rapamycin treatment alone. Colocalized delivery of rapamycin and paclitaxel
  also showed a decrease in phosphorylation of FoxO proteins. Taken together, the
  effects of combination therapy led to synergistic enhancement of cell death by decreasing
  protein translation, increasing apoptosis, and decreasing cell cycle progression.
pmcid: PMC4088997
papertitle: Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic
  Targeting of the PI3K/Akt/mTOR Pathway.
reftext: Elvin Blanco, et al. Mol Ther. 2014 Jul;22(7):1310-1319.
pmc_ranked_result_index: '75645'
pathway_score: 0.9626656
filename: mt201427f5.jpg
figtitle: Rapamycin and paclitaxel nanoparticles synergistically target the PI3K/Akt/mTOR
  pathway by suppressing feedback loop Akt phosphorylation
year: '2014'
organisms: Homo sapiens
ndex: b4d017c8-ded8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4088997__mt201427f5.html
  '@type': Dataset
  description: Rapamycin and paclitaxel nanoparticles synergistically target the PI3K/Akt/mTOR
    pathway by suppressing feedback loop Akt phosphorylation. Rapamycin nanoparticle
    treatment alone caused a decrease in phosphorylated S6 and S6K, as well as 4E-BP1,
    and an increase in pAkt through feedback loop activation. Rapamycin and paclitaxel
    delivered within the same nanoparticle also led to a decrease in phosphorylated
    S6, S6K, and 4E-BP1, but resulted in a decrease in pAkt. Combination therapy also
    inhibited phosphorylation of PRAS40, Bad, and GSK3β, all previously shown to increase
    with rapamycin treatment alone. Colocalized delivery of rapamycin and paclitaxel
    also showed a decrease in phosphorylation of FoxO proteins. Taken together, the
    effects of combination therapy led to synergistic enhancement of cell death by
    decreasing protein translation, increasing apoptosis, and decreasing cell cycle
    progression.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BAD
  - AKT3
  - PIK3R6
  - AKT1
  - AKT2
  - PIK3CA
  - FOXO1
  - PIK3R5
  - PIK3R4
  - FOXO4
  - RPTOR
  - PIK3CB
  - FOXO3
  - IRS1
  - FOXO6
  - PIK3CG
  - MTOR
  - PTEN
  - PIK3CD
  - EIF4EBP1
  - AKT1S1
  - PIK3R3
  - paclitaxel
  - Rapamycin
  - Cancer
genes:
- word: Bad
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO4
  entrez: '4303'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: IRS1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO6
  entrez: '100132074'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: 4EBP1
  symbol: 4E-BP1
  source: hgnc_alias_symbol
  hgnc_symbol: EIF4EBP1
  entrez: '1978'
- word: PRAS40
  symbol: PRAS40
  source: hgnc_alias_symbol
  hgnc_symbol: AKT1S1
  entrez: '84335'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
chemicals:
- word: paclitaxel
  source: MESH
  identifier: D017239
- word: Rapamycin
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC4088997__F5
redirect_from: /figures/PMC4088997__F5
figtype: Figure
---
